Recent stock market swings reveal potential cracks in the artificial intelligence rally. High valuations in AI stocks are causing concern about a speculative bubble. Investors are watching for signs of a pullback. Comparisons are being made to past market manias. Valuations remain elevated, with risks around spending and capacity. Some leaders dismiss bubble fears, while others acknowledge potential impacts.
Wockhardt shares rocket 19% after FDA approval for antibiotic targeting drug-resistant infections. Check details
Wockhardt’s shares surged 19% after the U.S. FDA approved ZAYNICH, a novel intravenous antibiotic for complicated urinary tract infections. The drug, combining cefepime and zidebactam,
June 1, 2026